Abstract
Introducción: Se están utilizando diversos fármacos para la sintomatología que causa la
COVID-19 sin que estén aprobados para esos fines. Muchos de estos medicamentos tienen
un margen de seguridad pequeño y tienen efectos adversos muy riesgosos para la salud, por
lo que requieren de receta médica y, sobre todo, de monitoreo y seguimiento médico.
Lamentablemente hay muchos casos de automedicación en Perú y Bolivia que requieren de
un pronto abordaje.
Objetivo: Efectuar una revisión sistemática de la literatura científica que presenta evidencias
sobre la efectividad y las reacciones adversas de los fármacos que se usan en la actualidad
contra la COVID-19 en Perú y Bolivia.
Métodos: Investigación cualitativa a partir de la revisión sistemática de la literatura científica
disponible en PubMed, así como la normativa nacional de Perú y Bolivia relacionada con
etiología, epidemiología, sintomatología, los tratamientos aprobados y descontinuados por
ambos países desde la agudización de la crisis de la COVID-19 y los estudios clínicos que se
han completado hasta la fecha.
Conclusiones: Los medicamentos usados en Perú y Bolivia para el tratamiento de la COVID19 tienen efectos secundarios y posibles riesgos a la salud de las personas que
lamentablemente se automedican. Se requiere un mayor control de estos medicamentos para
evitar su libre adquisición, mejorar la estrategia nacional y regional para evaluar los posibles
tratamientos sintomatológicos de la COVID-19, para lo que se debe tener en cuenta la alta
probabilidad de sobrevivencia de la enfermedad y el riesgo que representa el empleo de estos
fármacos, lo que podría causar en el futuro serios efectos adversos a la salud pública de los
dos países.
Introduction: Various drugs are being used against the symptoms caused by COVID-19, without being approved for these purposes. Many of these drugs have small safety margin and very risky adverse effects on health, a reason why they require prescription and, above all, medical monitoring and follow-up. Unfortunately, there are many cases of self-medication in Peru and Bolivia that require prompt management. Objective: To carry out a systematic review of the scientific literature that presents evidence about the effectiveness and adverse reactions of the drugs currently used against COVID-19 in Peru and Bolivia. Methods: Qualitative research based on the systematic review of the scientific literature available in PubMed, as well as in the national regulations of Peru and Bolivia related to the etiology, epidemiology, symptoms, as well as treatments approved and discontinued by both countries since the exacerbation of the COVID-19 crisis and the completion of clinical studies to date. Conclusions: The drugs used in Peru and Bolivia for treating COVID-19 have side effects and possible risks to the health of people who unfortunately self-medicate. Greater control of these drugs is required to avoid their free acquisition, and to improve the national and regional strategy to evaluate the possible symptomatic treatments of COVID-19, taking into consideration the high probability of survival of the disease and the risk posed by using these drugs, which, in the future, could cause serious adverse effects on public health in the two countries.
Introduction: Various drugs are being used against the symptoms caused by COVID-19, without being approved for these purposes. Many of these drugs have small safety margin and very risky adverse effects on health, a reason why they require prescription and, above all, medical monitoring and follow-up. Unfortunately, there are many cases of self-medication in Peru and Bolivia that require prompt management. Objective: To carry out a systematic review of the scientific literature that presents evidence about the effectiveness and adverse reactions of the drugs currently used against COVID-19 in Peru and Bolivia. Methods: Qualitative research based on the systematic review of the scientific literature available in PubMed, as well as in the national regulations of Peru and Bolivia related to the etiology, epidemiology, symptoms, as well as treatments approved and discontinued by both countries since the exacerbation of the COVID-19 crisis and the completion of clinical studies to date. Conclusions: The drugs used in Peru and Bolivia for treating COVID-19 have side effects and possible risks to the health of people who unfortunately self-medicate. Greater control of these drugs is required to avoid their free acquisition, and to improve the national and regional strategy to evaluate the possible symptomatic treatments of COVID-19, taking into consideration the high probability of survival of the disease and the risk posed by using these drugs, which, in the future, could cause serious adverse effects on public health in the two countries.
Translated title of the contribution | Tratamiento de la COVID-19 en Perú y Bolivia y los riesgos de la automedicación |
---|---|
Original language | American English |
Journal | Revista Cubana de Farmacia |
State | Published - 1 Jan 2020 |
Externally published | Yes |
COAR
- Article
OECD Category
- Negocios, Administración
Ulima Repository Category
- Ciencias / Medicina y Salud
Ulima Repository Subject
- Automedicación
- Bolivia
- COVID-19
- Pandemias
- Pandemics
- Perú
- Self medication
- Terapéutica
- Therapeutics